| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | Seth M Steinberg | |
| Franz O Smith | |||
| James C Yang | |||
| Marybeth S Hughes | |||
| Richard M Sherry | |||
| Udai S Kammula | |||
| Richard E Royal | |||
| Jacob A Klapper | |||
| Stephanie G Downey | |||
| P2860 | cites work | Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer | Q70649453 |
| Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma | Q70671888 | ||
| The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL | Q71067297 | ||
| Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response | Q77317862 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy | Q28208220 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 | ||
| Reporting results of cancer treatment | Q29620070 | ||
| Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. | Q33499384 | ||
| Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. | Q33880227 | ||
| Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer | Q34536176 | ||
| Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy | Q34723863 | ||
| Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy | Q40382856 | ||
| Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma | Q40688824 | ||
| Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial | Q40713184 | ||
| Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis | Q40731729 | ||
| Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. | Q41773666 | ||
| Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. | Q53675646 | ||
| A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy | Q68926133 | ||
| Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients | Q69548004 | ||
| Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer | Q69555390 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| interleukins | Q194908 | ||
| renal cell carcinoma | Q1164529 | ||
| metastatic renal cell carcinoma | Q19000948 | ||
| P304 | page(s) | 293-301 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. | |
| P478 | volume | 113 |
| Q55030506 | A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model. |
| Q38373731 | A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma |
| Q58700691 | A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2 |
| Q35093466 | A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma |
| Q41963078 | Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy |
| Q96811980 | Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma |
| Q28080113 | Advances in Cancer Immunotherapy in Solid Tumors |
| Q41687389 | Advances on immunotherapy in genitourinary and renal cell carcinoma |
| Q35446852 | Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after |
| Q93129949 | Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation |
| Q36016696 | Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice |
| Q90606767 | CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression |
| Q36177214 | CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model |
| Q47102297 | Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches |
| Q41064873 | Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations |
| Q38737924 | Cancer Immunotherapy: Whence and Whither |
| Q38600417 | Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations. |
| Q38106230 | Cancer immunotherapies, their safety and toxicity. |
| Q38011650 | Challenges in T cell receptor gene therapy. |
| Q92529497 | Chemoimmunotherapy in Advanced Renal Cell Carcinoma: A Case Report of a Long-Term Survivor Adjunctly Treated with Viscum album Extracts |
| Q35196765 | Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience |
| Q39067371 | Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma |
| Q50545440 | Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25. |
| Q34539858 | Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells |
| Q37527224 | Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. |
| Q38743775 | Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. |
| Q38214976 | Current management and future perspectives of metastatic renal cell carcinoma |
| Q39384263 | DNA Damage and Repair Biomarkers of Immunotherapy Response |
| Q35077925 | Differential expression of proteins in naïve and IL-2 stimulated primary human NK cells identified by global proteomic analysis |
| Q61443377 | Directed evolution of super-secreted variants from phage-displayed human Interleukin-2 |
| Q33828919 | Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma |
| Q33415481 | Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program |
| Q38587958 | Emerging therapeutic approaches in renal cell carcinoma |
| Q91933365 | Emerging trends in immunotherapy for pediatric sarcomas |
| Q88312736 | Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma |
| Q37576033 | Exploiting the curative potential of adoptive T-cell therapy for cancer |
| Q39699164 | Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. |
| Q90600541 | First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options |
| Q55346727 | G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas. |
| Q34645898 | Genetically engineered T cells for the treatment of cancer |
| Q37409283 | Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma |
| Q36954166 | Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions |
| Q27853203 | Heme oxygenase-1 is a predictive biomarker for therapeutic targeting of advanced clear cell renal cell carcinoma treated with sorafenib or sunitinib |
| Q35674197 | High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma |
| Q47188564 | High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features |
| Q58106924 | IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages |
| Q39880454 | IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells |
| Q34423519 | IL-2: the first effective immunotherapy for human cancer. |
| Q34418482 | Identification of a set of genes associated with response to interleukin-2 and interferon-α combination therapy for renal cell carcinoma through genome-wide gene expression profiling |
| Q47592718 | Immune checkpoint inhibitors in renal cell carcinoma |
| Q55418935 | Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. |
| Q91238304 | Immuno-Oncology in the Era of Personalized Medicine |
| Q37987862 | Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response? |
| Q26776184 | Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies |
| Q39120161 | Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go? |
| Q90623091 | Immunotherapy Against Gliomas: is the Breakthrough Near? |
| Q35802508 | Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review |
| Q93027295 | Immunotherapy in Urological Tumors |
| Q40105858 | Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease |
| Q38834167 | Immunotherapy of advanced renal cell carcinoma: Current and future therapies |
| Q37725613 | Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects |
| Q33977597 | Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells |
| Q47287952 | Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry |
| Q26852703 | Insights into cytokine-receptor interactions from cytokine engineering |
| Q28068375 | Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells |
| Q35164811 | Interferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy |
| Q37183063 | Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer |
| Q58779761 | Interleukin-15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine model |
| Q53076079 | Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? |
| Q38756417 | Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer |
| Q36307736 | Landscape of Tumor Antigens in T Cell Immunotherapy |
| Q53207573 | Long-term complete response to very-low-dose interleukin-2 therapy in patients with metastatic renal cell carcinoma: report of two cases. |
| Q36279172 | Magnetic Resonance Imaging as a Biomarker for Renal Cell Carcinoma |
| Q57490861 | Mapping Determinants of Cytokine Signaling via Protein Engineering |
| Q39418546 | Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy |
| Q37191335 | Metastatic Renal Cell Carcinoma Presenting as Painful Chewing Successfully Treated with Combined Nivolumab and Sunitinib |
| Q38264616 | Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art |
| Q38909407 | Molecular dissection of the interactions of an antitumor interleukin-2-derived mutein on a phage display-based platform |
| Q37066106 | Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape |
| Q37393000 | Myeloid-derived suppressor cells: a novel therapeutic target |
| Q34221846 | NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma |
| Q40122658 | Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine |
| Q38020243 | Neoadjuvant and adjuvant treatment of renal cell carcinoma |
| Q55510561 | Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy. |
| Q38755931 | PD-1 and PD-L1 antibodies in cancer: current status and future directions |
| Q26865789 | PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence |
| Q37596748 | PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases |
| Q36890941 | PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells |
| Q37778312 | Perspectives in drug development for metastatic renal cell cancer |
| Q47425474 | Phagekines: Screening Binding Properties and Biological Activity of Functional Cytokines Displayed on Phages |
| Q56899396 | Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma |
| Q99605164 | Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma |
| Q38110934 | Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma |
| Q39415827 | Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma. |
| Q64233226 | Radiation Therapy and its Effects Beyond the Primary Target: An Abscopal Effect |
| Q37998451 | Raising the bar: the curative potential of human cancer immunotherapy. |
| Q38981347 | Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment |
| Q47131174 | Regulatory T cells control toxicity in a humanized model of IL-2 therapy |
| Q30248354 | Renal cell cancer: overview of the current therapeutic landscape. |
| Q52724797 | Renal cell carcinoma: a review of biology and pathophysiology. |
| Q39222755 | Renal cell carcinoma: new insights and challenges for a clinician scientist |
| Q34021843 | Retrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma |
| Q52566588 | Role of metastasis-directed treatment in kidney cancer. |
| Q51034447 | Sequential Therapy in Metastatic Renal Cell Carcinoma. |
| Q38072402 | Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance |
| Q35545785 | Single-Cell Characterization of in vitro Migration and Interaction Dynamics of T Cells Expanded with IL-2 and IL-7. |
| Q38720307 | Stereotactic ablative body radiotherapy for primary kidney cancer: what have we learned from prospective trials and what does the future hold? |
| Q39089402 | Strategies to overcome therapeutic resistance in renal cell carcinoma |
| Q26852704 | Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer |
| Q38860651 | Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma |
| Q33434845 | Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience |
| Q53179258 | Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma. |
| Q36552580 | T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein |
| Q38816851 | Targeted Therapies Combined With Immune Checkpoint Therapy. |
| Q93010833 | Targeted antibody and cytokine cancer immunotherapies through collagen affinity |
| Q39425380 | Targeted therapies for renal cell carcinoma |
| Q52657032 | Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. |
| Q100455154 | Targeting the HIF2-VEGF axis in renal cell carcinoma |
| Q38259461 | Th1 cytokine-based immunotherapy for cancer. |
| Q24616434 | The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses |
| Q26777889 | The Toxicity and Benefit of Various Dosing Strategies for Interleukin-2 in Metastatic Melanoma and Renal Cell Carcinoma |
| Q34608796 | The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). |
| Q47129923 | The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. |
| Q34983681 | The contemporary role of surgery in kidney cancer |
| Q47097756 | The current status of immunobased therapies for metastatic renal-cell carcinoma |
| Q39338052 | The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer |
| Q35996059 | The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer |
| Q49216382 | The potential and promise of IL-15 in immuno-oncogenic therapies |
| Q26783291 | The potential of radiotherapy to enhance the efficacy of renal cell carcinoma therapy |
| Q34402325 | The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014 |
| Q34255232 | The role of interleukin-2 during homeostasis and activation of the immune system |
| Q92092437 | The role of the immune system in brain metastasis |
| Q38825250 | The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. |
| Q44834803 | The treating scenario in genitourinary oncology: what is new? Part 1. |
| Q34786691 | Therapeutic cancer vaccines: are we there yet? |
| Q37999655 | Treatment selection in metastatic renal cell carcinoma: expert consensus |
| Q41561012 | Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era. |
| Q33689478 | Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer |
| Q37697631 | Update on systemic therapies of metastatic renal cell carcinoma |
| Q37895254 | Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma |
| Q59351045 | YY1 Upregulates Checkpoint Receptors and Downregulates Type I Cytokines in Exhausted, Chronically Stimulated Human T Cells |
Search more.